CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Cost-effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany
DOI 10.1055/s-0031-1280949
Bibliografische Angaben
Nachweis in CareLit
Autor:innenCC Adarkwah, A Gandjour
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe08/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the USA. Angiotensin-converting enzyme (ACE) inhibitors slow down the progression of renal disease and therefore provide a renal-protective effect. However, uncertainty exists concerning the best time to start with ACE-inhibitor therapy. Furthermore, about 10% of patients develop ACE-inhibitor induced cough and thus are elig…
Zitieren
Zitierempfehlung
CC Adarkwah, A Gandjour (2011) Cost-effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Diabetologie und Stoffwechsel (08). https://doi.org/10.1055/s-0031-1280949
Mit CareLit weiterarbeiten